![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif)
sunitinib malate![Patient Information Patient Information](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/btn-patient-info.gif) The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif)
Synonym: | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | sunitinib | | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | US brand name: | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | Sutent | | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | SU011248 SU11248 | | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure name: | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) | 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) | | ![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509173918im_/http://www.cancer.gov/images/spacer.gif) |